This content is only available within our institutional offering.
19 Mar 2020
ROCHE - BUY - Top Picks | CHF360(+24%) Roche initiates phase III trial to test Actemra in patients with severe Covid-19 pneumonia
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE - BUY - Top Picks | CHF360(+24%) Roche initiates phase III trial to test Actemra in patients with severe Covid-19 pneumonia
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
19 Mar 2020 -
Author:
Eric Le Berrigaud -
Pages:
3
ROCHE - BUY - Top Picks | CHF360(+24%)
Roche initiates phase III trial to test Actemra in patients with severe Covid-19 pneumonia
First evidence of efficacy was showed in a small trial in China
No meaningful financial impact from the situation to date